An inhibitor of mutant EGFRs
此产品仅用于科学研究,我们不为任何个人用途提供产品和服务
Aflutinib is an inhibitor of mutant EGFRs.1 It is selective for EGFRL858R, EGFRG719X, EGFRL858R, EGFRL861A, and EGFRT790M mutant EGFRs over wild-type EGFR. Aflutinib (10 and 30 mg/kg) reduces tumor growth in an EGFRL858R and EGFRT790M-expressing LU1868 non-small cell lung cancer (NSCLC) patient-derived xenograft (PDX) mouse model.
1.Shi, Y., Zhang, S., Hu, X., et al.Safety, clinical activity, and pharmacokinetics of alflutinib (AST2818) in patients with advanced NSCLC with EGFR T790M mutationJ. Thorac. Oncol.15(6)1015-1026(2020)
没有评价数据